

HR 6576

Drug-Price Transparency in Communications Act

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 26, 2018

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jul 27, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/6576>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 27, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 2157	Identical bill	Nov 16, 2017: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jul 26, 2018)

Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.

Actions Timeline

- **Jul 27, 2018:** Referred to the Subcommittee on Health.
- **Jul 26, 2018:** Introduced in House
- **Jul 26, 2018:** Referred to the House Committee on Energy and Commerce.